BRPI0908098A2 - Beloxepina, composição, métodos para tratar dor em um mamífero, para inibir a recaptação de ne, para antagonizar um receptor de 5ht2 e para tratar um distúrbio em um paciente que é responsivo ao tratamento com um composto nri e com um composto antagonista de 5ht2 - Google Patents
Beloxepina, composição, métodos para tratar dor em um mamífero, para inibir a recaptação de ne, para antagonizar um receptor de 5ht2 e para tratar um distúrbio em um paciente que é responsivo ao tratamento com um composto nri e com um composto antagonista de 5ht2Info
- Publication number
- BRPI0908098A2 BRPI0908098A2 BRPI0908098-8A BRPI0908098A BRPI0908098A2 BR PI0908098 A2 BRPI0908098 A2 BR PI0908098A2 BR PI0908098 A BRPI0908098 A BR PI0908098A BR PI0908098 A2 BRPI0908098 A2 BR PI0908098A2
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- compound
- beloxepine
- antagonizing
- reuptake
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 title 1
- 108091005479 5-HT2 receptors Proteins 0.000 title 1
- 241000124008 Mammalia Species 0.000 title 1
- 230000003042 antagnostic effect Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000003215 serotonin 5-HT2 receptor antagonist Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Pregnancy & Childbirth (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2991308P | 2008-02-19 | 2008-02-19 | |
| US2991608P | 2008-02-19 | 2008-02-19 | |
| US2991508P | 2008-02-19 | 2008-02-19 | |
| US5092108P | 2008-05-06 | 2008-05-06 | |
| PCT/US2009/034461 WO2009105507A2 (en) | 2008-02-19 | 2009-02-19 | Beloxepin, its enantiomers, and analogs thereof for the treatment of pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0908098A2 true BRPI0908098A2 (pt) | 2015-08-18 |
Family
ID=40986169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0908098-8A BRPI0908098A2 (pt) | 2008-02-19 | 2009-02-19 | Beloxepina, composição, métodos para tratar dor em um mamífero, para inibir a recaptação de ne, para antagonizar um receptor de 5ht2 e para tratar um distúrbio em um paciente que é responsivo ao tratamento com um composto nri e com um composto antagonista de 5ht2 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP2285818A4 (https=) |
| JP (1) | JP2011512414A (https=) |
| KR (1) | KR20100137473A (https=) |
| CN (1) | CN102007139A (https=) |
| AU (1) | AU2009215541A1 (https=) |
| BR (1) | BRPI0908098A2 (https=) |
| CA (1) | CA2715192A1 (https=) |
| IL (1) | IL207668A0 (https=) |
| MX (1) | MX2010009110A (https=) |
| NZ (2) | NZ594937A (https=) |
| WO (1) | WO2009105507A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090233959A1 (en) | 2008-02-19 | 2009-09-17 | Adolor Corporation | Beloxepin and analogs for the treatment of pain |
| CN113546174A (zh) | 2015-02-25 | 2021-10-26 | 加利福尼亚大学董事会 | 用于治疗病症的5ht激动剂 |
| CN106243096B (zh) * | 2016-07-29 | 2019-11-29 | 上海璃道医药科技有限公司 | 三环类药物的新用途 |
| US10966938B2 (en) | 2019-01-04 | 2021-04-06 | Jonand4, Llc | Composition and method for preventing or treating hangover symptoms |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE62754B1 (en) * | 1988-08-26 | 1995-02-22 | Akzo Nv | Tetracyclic antidepressants |
| US5663178A (en) | 1995-02-06 | 1997-09-02 | Eli Lilly And Company | Tetrahydro-beta carbolines |
| TW440563B (en) | 1996-05-23 | 2001-06-16 | Hoffmann La Roche | Aryl pyrimidine derivatives and a pharmaceutical composition thereof |
| US5952331A (en) | 1996-05-23 | 1999-09-14 | Syntex (Usa) Inc. | Aryl pyrimidine derivatives |
| GB0004003D0 (en) * | 2000-02-22 | 2000-04-12 | Knoll Ag | Therapeutic agents |
| GB0019950D0 (en) | 2000-08-12 | 2000-09-27 | Smithkline Beecham Plc | Compounds |
| CA2509142A1 (en) * | 2002-12-11 | 2004-06-24 | Pharmacia & Upjohn Company Llc | Combination for the treatment of adhd |
| BRPI0415683A (pt) * | 2003-11-03 | 2006-12-19 | Warner Lambert Co | inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central |
| US20080119477A1 (en) * | 2004-12-13 | 2008-05-22 | Smith Brian M | N-Biaryl and N-Arylheteroaryl Piperazine Derivatives as Modulators of the 5Ht2c Receptor Useful For the Treatment of Disorders Related Thereto |
| EP1846415B1 (en) * | 2005-01-27 | 2012-08-01 | Janssen Pharmaceutica NV | Heterocyclic tetracyclic tetrahydrofuran derivatives as 5ht2 inhibitors in the treatment of cns disorders |
| US20060293309A1 (en) * | 2005-03-28 | 2006-12-28 | Dynogen Pharmaceuticals, Inc. | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors |
| PE20070544A1 (es) * | 2005-09-29 | 2007-07-26 | Wyeth Corp | Derivados de benzotiadiazolilfenilalquilamina |
| CA2647835A1 (en) * | 2006-03-28 | 2007-10-04 | Neopro Labs, Llc | Methods and compositions for treating conditions |
| GB0608655D0 (en) * | 2006-05-03 | 2006-06-14 | Merck Sharp & Dohme | Therapeutic Treatment |
| US20070281924A1 (en) * | 2006-05-31 | 2007-12-06 | Gaeta Federico C | MIF inhibitors for treating neuropathic pain and associated syndromes |
-
2009
- 2009-02-19 BR BRPI0908098-8A patent/BRPI0908098A2/pt not_active IP Right Cessation
- 2009-02-19 CN CN2009801138213A patent/CN102007139A/zh active Pending
- 2009-02-19 NZ NZ594937A patent/NZ594937A/xx not_active Application Discontinuation
- 2009-02-19 KR KR1020107021010A patent/KR20100137473A/ko not_active Withdrawn
- 2009-02-19 NZ NZ587896A patent/NZ587896A/en not_active IP Right Cessation
- 2009-02-19 AU AU2009215541A patent/AU2009215541A1/en not_active Abandoned
- 2009-02-19 WO PCT/US2009/034461 patent/WO2009105507A2/en not_active Ceased
- 2009-02-19 EP EP09712730A patent/EP2285818A4/en not_active Withdrawn
- 2009-02-19 CA CA2715192A patent/CA2715192A1/en not_active Abandoned
- 2009-02-19 MX MX2010009110A patent/MX2010009110A/es not_active Application Discontinuation
- 2009-02-19 JP JP2010547737A patent/JP2011512414A/ja not_active Withdrawn
-
2010
- 2010-08-18 IL IL207668A patent/IL207668A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2285818A2 (en) | 2011-02-23 |
| IL207668A0 (en) | 2010-12-30 |
| KR20100137473A (ko) | 2010-12-30 |
| MX2010009110A (es) | 2010-11-30 |
| CA2715192A1 (en) | 2009-08-27 |
| WO2009105507A3 (en) | 2010-01-14 |
| WO2009105507A2 (en) | 2009-08-27 |
| NZ594937A (en) | 2013-03-28 |
| NZ587896A (en) | 2011-09-30 |
| AU2009215541A1 (en) | 2009-08-27 |
| JP2011512414A (ja) | 2011-04-21 |
| CN102007139A (zh) | 2011-04-06 |
| EP2285818A4 (en) | 2011-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1009381A2 (pt) | compostos, composição farmacêutica, método para tratar doença ou condição associada com função de trap1 em sujeito em necessidade do mesmo e uso de compostos e composição farmacêutica | |
| BRPI0719276A2 (pt) | Métodos para tratar, prevenir ou controlar uma doença associada com uma mutação sem sentido, para tratar, prevenir ou reduzir tosse, para aumentar expressão de distrofina em músculo de um paciente e para administrar um composto. | |
| IL243574B (en) | A pharmaceutical preparation for use in the treatment of a disease treatable by blocking purine receptors | |
| EP2406765A4 (en) | DEVICE FOR ADMINISTERING A MEDICAMENT TO A PATIENT WITH RESTRICTED PATIENT-SIDED ACCESS TO THE MEDICAMENT IN THE CASE OF CONTRAINDICATIONS AND APPLICATION METHOD THEREFOR | |
| BR112013013417A2 (pt) | composto, medicamento, métodos para inibir a acetil-coa carboxilase em um mamífero, e de profilaxia ou tratamento da obesidade ou diabete em um mamífero, e, uso de um composto ou sal | |
| EP2229171A4 (en) | METHOD AND COMPOSITIONS FOR TREATING POST-OPERATIVE PAIN WITH A LOCAL ANESTHETIC | |
| IL223783B (en) | Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine | |
| SI2397158T1 (sl) | Kombinacija spojin morfinana in antidepresivov za zdravljenje psevdobulbarnih vplivov | |
| BRPI0917004A2 (pt) | composto, composição farmacêutica, uso de um composto, e, métodos para melhorar a qualidade do sono, para tratar insônia, e para tratar ou controlar obesidade em um paciente mamífero em necessidade deste | |
| MX2011008450A (es) | Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos. | |
| BRPI0916890A2 (pt) | composto, composição farmacêutica, métodos para elicitar um efeito agonista, e um efeito antagonista de um receptor de gip, para tratar condições ou doeças, para tratar distúrbios, para tratar ou prevenir causas secundárias de diabete, e para estimular secreção de insulina em um indivíduo, e, uso de um composto | |
| IL213526A0 (en) | Methods for treating acute myocardial infarctions and associated disorders | |
| BR112013025386A2 (pt) | combinação de um composto, composto de fórmula ia ou um sal farmaceuticamente aceitável do mesmo, método para tratamento de uma doença ou afecção modulada por mutação braf v600e e altos níveis de pakt em um mamífero e uso | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| BRPI1007636A2 (pt) | Composição farmacêutica, forma de dosagem, método para a preparação da composição farmacêutica, método de preparação da forma de dosagem e método de tratamento da dor | |
| IL205704A (en) | Use of alpha adrenoceptor inhibitors in the preparation of a drug for the treatment of pig fever | |
| BR112013016862A2 (pt) | combinação de um agonista de opioide e um antagonista de opioide no tratamento de doença de parkinson | |
| HUE050319T2 (hu) | Kompozíciók és eljárások alkoholfogyasztással kapcsolatos rendellenességek, fájdalom és más betegségek kezelésére | |
| IN2012DN02782A (https=) | ||
| BR112012002246A2 (pt) | composto, composto ou sal farmaceutico aceitavel deste, composição farmaceutica, metodo para inibir, tratar e/ou reduzir o declinio cognitivol e/ou doença de akzhmer em um paciente | |
| EP2257543A4 (en) | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, PROCESSING METHODS AND PREPARATION METHODS THEREOF | |
| SI2355822T1 (sl) | Zdravljenje kognitivnih motenj z (R)-7-kloro-N-(kinuklidin-3-il)benzo(b)tiofen-2-karboksamidom in njegovimi farmacevtsko sprejemljivimi solmi | |
| IL209816A0 (en) | Combination of pilocarpin and methimazol for treating charcot-marietooth disease and related disorders | |
| BR112013001422A2 (pt) | metodo para tratar ou previnir disturbios induzidos por l-dopa, agonista dopamina e/ou acentuador de dopamina em um individuo que necessita dos mesmos, agente, composição, uso de ou mais agentes e metodo para tratar a doença de parkinson | |
| IL216258A0 (en) | Serotonin 5-ht3 receptor antagonists for use in the treatment of lesional vestibular disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |